Serum-free Media Market Size & Share 2026-2035

Serum-free Media Market Size

The serum-free media market was valued at USD 2.1 billion in 2025. The market is projected to grow from USD 2.3 billion in 2026 to USD 5.9 billion in 2035, growing at a CAGR of 11.2% over the analysis period, as per the latest report published by Global Market Insights Inc.

Increasing demand for biopharmaceutical production, regenerative medicine, vaccine development, and growing cell & gene therapy applications are key factors driving market growth. Rising incidences of chronic diseases such as cancer, autoimmune disorders, and rare genetic diseases continue to accelerate demand for advanced biologics and cell-based therapies, thereby supporting serum-free media adoption. For instance, as per the American Association for Cancer Research (AACR), there were an estimated 20 million new cancer cases and over 10.3 million deaths from cancer in 2025. Further, in 2025, the U.S. FDA approved 46 novel drugs, comprising 12 biologics, accounting for roughly 25% of total approvals, including antibody-drug conjugates (ADCs), fusion proteins, and both mono- and bispecific monoclonal antibodies. These trends continue to strengthen the requirement for serum-free media across research and for commercial manufacturing.

Serum-free media are cell culture media formulations that do not contain animal serum and instead contain defined nutrients, growth factors, hormones, and supplements to support cellular growth and proliferation in controlled laboratory environments. These are widely used in biologics manufacturing, vaccine production, stem cell research, tissue engineering, and cell & gene therapy development due to their excellent batch-to-batch consistency, enhanced safety profile, and compatibility with regulatory standards.

Major players operating in the serum-free media market include Thermo Fisher Scientific, Merck KGaA, Cytiva, Sartorius AG, and FUJIFILM Irvine Scientific. These players compete through strong product portfolios, global reach, and ongoing innovation in serum-free and specialized media, while expanding capacity and partnerships to support growing demand in biologics and advanced therapies.

Between 2022 and 2024, the serum-free media market experienced steady expansion, supported by increasing investments in biopharmaceutical manufacturing and advanced therapy development. The market grew from USD 1.7 billion in 2022 to USD 1.9 billion in 2024. Growing demand for monoclonal antibodies, recombinant proteins, viral vectors, and stem cell-based therapeutics accelerated the use of serum-free formulations in both upstream bioprocessing and clinical research applications. Furthermore, technological advancements have enhanced cell viability, scalability, and protein yield. For instance, in July 2023, Lonza Group launched the TheraPRO CHO media system to improve productivity and protein quality for biopharmaceutical manufacturing applications.

Serum-free Media Market Trends

• One of the major trends in the serum-free media industry is the growing shift from traditional serum-containing media to serum-free and chemically defined media formulations. This shift is driven by the increasing demand for higher reproducibility, lower risk of contamination, improved scalability and increased regulatory compliance in biopharmaceutical manufacturing.
• Biopharmaceutical companies are moving more quickly to adopt serum-free media for the purpose of ensuring batch-to-batch consistency and enabling standardized manufacturing processes for biologics, vaccines, and advanced therapies.
• Further, the rapid growth of cell and gene therapies (CGTs) is also significantly increasing the demand for serum-free media. As the global CGT pipeline continues to expand, manufacturers are focusing on customized serum-free media solutions tailored to specific therapeutic applications, thereby accelerating market growth.
• In addition, the rising outsourcing activities to contract development and manufacturing organizations (CDMOs) are driving the demand for serum-free media. CDMOs require scalable, regulatory-compliant, and high-quality media solutions to support multiple biologics and advanced therapy manufacturing programs.
• Further, increasing investments in global biomanufacturing infrastructure, particularly across Asia Pacific and other emerging markets, are further strengthening demand for reliable serum-free media supply.
• Lastly, the increasing global prevalence of chronic diseases such as cancer, diabetes, autoimmune diseases, and rare genetic disorders is expected to significantly drive demand in the serum-free media.
• According to the American Cancer Society, approximately 2,001,140 new cancer cases and 611,720 cancer deaths were projected in the U.S. in 2024. Additionally, the International Agency for Research on Cancer projected that global cancer cases could exceed 35 million by 2050, representing a 77% increase compared to 2022.
• As the burden of chronic diseases continues to rise, the demand for advanced biologics, monoclonal antibodies, stem cell therapies, and immunotherapies such as CAR-T therapies is expected to increase substantially. These therapies rely heavily on high-quality serum-free media to support cell growth, proliferation, viability, and therapeutic performance, making advanced serum-free media formulations critical for next-generation biopharmaceutical manufacturing and regenerative medicine applications.

Serum-free Media Market Analysis

Based on the product type, the serum-free media market is classified into CHO media, HEK 293 media, BHK media, VERO cell media, insect cell media, immune cell media, and other serum-free media. The CHO media segment dominated the market with a revenue of USD 801.5 million in 2025.

• CHO media are among the widely used serum-free media owing to the widespread use of CHO cell lines in the production of monoclonal antibodies, recombinant proteins, vaccines, and other biologics.
• CHO cells are considered the industry standard for biopharmaceutical manufacturing due to their ability to achieve high protein expression and scalability in large bioreactors.
• Further, the increasing number of biologics and biosimilars entering clinical development and commercialization has significantly accelerated the demand for optimized serum-free CHO media formulations.
• The HEK 293 media segment accounts for the second-largest share of 11.6% in 2025 due to the extensive use of HEK 293 cell lines in viral vector production, gene therapy development, vaccine manufacturing, and recombinant protein expression.
• The rapid expansion of cell and gene therapy pipelines, particularly adeno-associated virus (AAV) and lentiviral vector-based therapies, continues to drive demand for optimized serum-free HEK 293 media formulations that support high transfection efficiency, scalability, and enhanced viral yields.
• On the other hand, the VERO cell media segment is expected to witness high growth at a CAGR of 11.8% owing to the increasing use of VERO cell lines in viral vaccine production, particularly for influenza, rabies, polio, and emerging infectious disease vaccines, along with rising demand for serum-free vaccine manufacturing processes.

Based on the form, the serum-free media market is classified into liquid media and semi-solid and solid media. The liquid media segment dominated the market in 2025 and is expected to reach USD 4.1 billion by 2035.

• Liquid media hold the largest share of the market due to their ease of handling, ready-to-use nature, faster preparation time and ability to provide consistent nutrient distribution during cell cultivation.
• Large-scale manufacturing processes for biologics widely prefer liquid serum-free media as it enhances operational efficiency, decreases the risk of contamination and provide better scalability in commercial bioprocessing environments.
• On the other hand, there is consistent growth in semi-solid and solid media, arising from their widespread use in cell isolation, colony formation assays, stem cell research and microbial culture applications.
• These media aid in the controlled growth of cells and are commonly used in research laboratories, diagnostics and in specialized cell culture applications.

Based on the application, the serum-free media market is classified into biopharmaceutical production, vaccine production, drug discovery & development, stem cell research & therapy, tissue engineering & regenerative medicine, and other applications. The biopharmaceutical production segment dominated the market with a market share of 41.2% in 2025.

• The biopharmaceutical production segment holds a prominent share owing to the rapid growth of the biopharmaceutical industry, coupled with high adoption of biologics, including monoclonal antibodies, vaccines, recombinant protein production, and cell therapy and gene therapy (CGT).
• For instance, more than 2,000 CGT trials are active globally, and the number of developers worldwide (around 1,400) has increased by more than 10% from 2021 to 2022, according to the Alliance for Regenerative Medicine.
• Moreover, the rising incidence of chronic conditions, coupled with the increasing need for targeted therapies, has led to the rapid development and commercialization of biologics, thereby fueling the growth of the serum-free media market.
• In addition, advancements in bioprocessing technology, the transition towards commercial-scale production, and the increasing acceptance of single-use bioreactors have also supported the market growth.
• The vaccine production segment held the second-largest market share of 15.3% in 2025 in the serum-free media market due to the increasing global demand for viral and recombinant vaccines. Serum-free media are widely used in vaccine manufacturing as it improves production consistency, reduce contamination risks, and support regulatory compliance in large-scale bioprocessing.
• The stem cell research & therapy segment, on the other hand, is expected to grow at a CAGR of 11.7% over the forecast period, owing to the increasing investments in stem cell research and rising demand for advanced therapies for chronic diseases.

Based on the end use, the serum-free media market is classified into pharmaceutical & biotechnology companies, clinical research organizations (CROs), academic & research institutions, and other end users. The pharmaceutical and biotechnology companies’ segment is expected to reach USD 2.2 billion by 2035, maintaining its dominance due to its role in the development and manufacturing of biologics, vaccines, and cell-based therapies.

• These companies utilize advanced cell culture techniques to produce high-quality therapeutic products, including monoclonal antibodies, gene therapies, and regenerative treatments.
• Advancements in genomics and targeted therapies have led to an increased demand for personalized medicine, which in turn drives the need for specialized serum-free cell culture media in drug development and production.
• In addition, the growing focus on personalized medicine, targeted therapies, and precision biologics has significantly increased the demand for serum-free media for biomanufacturing processes.
• Furthermore, clinical research organizations (CROs) are witnessing growing demand for serum-free media due to the increasing outsourcing of preclinical research, biologics testing, and cell-based assay development by pharmaceutical and biotechnology companies. CROs rely heavily on high-quality serum-free media to support efficient drug discovery, toxicity studies, and advanced therapeutic research.

North America Serum-free Media Market

In 2025, North America secured a substantial market share of 38.9% in the global serum-free media industry and is expected to dominate throughout the forecast period.

• North America's biotechnology and pharmaceutical sectors maintain a strong global position through advanced research infrastructure and substantial life sciences investments.
• In addition, high funding for biopharmaceutical research and several initiatives aid in market growth. The U.S. government's funding of biomedical research through the National Institutes of Health (NIH) serves as a primary driver of this growth.
• For example, the National Institutes of Health (NIH) reached an annual budget of approximately USD 48 billion in fiscal year 2024, supporting over 300,000 research personnel and nearly 50,000 competitive grants. This funding facilitates healthcare and biotechnology breakthroughs, fostering the development of new therapies, medical technologies, and cell-based treatments.
• The U.S. market was valued at USD 601.4 million and USD 637 million in 2022 and 2023, respectively. The market size reached USD 720.8 million in 2025, growing from USD 673.5 million in 2024.
• The U.S. holds a significant share in the serum-free media market due to the robust biopharmaceutical sector in the country, coupled with a strong presence of the biotech industry and the research infrastructure.
• The country also benefits from the strong R&D investments. For instance, as per the Pharmaceutical Research and Manufacturers of America (PhRMA) trade group, in 2024, the research and development (R&D) expenditure of its member companies reached USD 104 billion worldwide.
• Furthermore, a high number of biologics approvals in the country, widespread adoption of advanced bioprocessing techniques, and support from regulatory authorities have further strengthened the position of U.S. in the market.

Europe Serum-free Media Market

Europe contributes substantially to the global market, owing to its well-established biopharmaceutical manufacturing industry, research infrastructure, and regulatory environment.

• The region also benefits from considerable investments in life science research and development, where Germany, UK, and France are key markets for biotechnology and pharmaceutical research and development.
• Furthermore, as per Pharmaphorum, as of 2025, European companies possess 25% of the global biopharma pipeline, thus contributing to continuous demand for serum-free cell culture media in this region.
• The regulatory support provided by regulatory authorities such as the European Medicines Agency, along with rising interest in biosimilar development, cell and gene therapies, and research and development collaborations, also contributes to market growth in this region.
• Additionally, continuous investments in biopharmaceutical manufacturing, increasing clinical trial activity, and strong regulatory alignment further reinforce the dominance of the regional market.

Asia Pacific Serum-free Media Market

The Asia Pacific market is anticipated to witness robust growth at a 11.9% CAGR over the analysis period.

• Asia Pacific represents a major and rising market for serum-free media, driven by the rapid growth of biopharmaceutical manufacturing in the region, strong clinical trial activity, and growing investments in the life sciences industry.
• For instance, the Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during this period.
• In addition, the region is witnessing rapid growth as a biologics manufacturing and outsourcing hub, driven by cost advantages and a large patient population.
• Furthermore, advancements in research facilities, government initiatives to support the biotechnology industry, and the adoption of advanced bioprocessing technology are fueling the growth of the market in the region.

Latin America Serum-free Media Market

Latin America is witnessing steady growth in the serum-free media industry owing to the expanding biopharmaceutical sector, increasing clinical research activities, and rising investments in biotechnology and vaccine manufacturing.

• Growing government support for local biomanufacturing capabilities, increasing prevalence of chronic diseases, and the gradual adoption of advanced biologics and biosimilars are driving demand for serum-free media in the region.
• In addition, the expansion of contract research and manufacturing activities, along with improving healthcare infrastructure and academic research capabilities, is further supporting market growth.
• The increasing focus on reducing dependence on imported biologics and strengthening domestic pharmaceutical production is also expected to accelerate adoption of serum-free media technologies across Latin America during the forecast period.

Middle East & Africa Serum-free Media Market

The Middle East & Africa market is expected to witness gradual growth over the forecast years.

• Countries such as Saudi Arabia, the UAE, and South Africa are increasingly investing in life sciences research, biopharmaceutical manufacturing, and healthcare modernization initiatives, creating opportunities for serum-free media adoption.
• Additionally, the rising burden of chronic and infectious diseases, along with increasing collaborations between regional healthcare institutions and global biopharmaceutical companies, is supporting demand for high-quality cell culture solutions.
• Although the market remains at a relatively early stage compared to developed regions, increasing research funding is expected to contribute to long-term market expansion in the region.

Serum-free Media Market Share

The global serum-free media industry is highly consolidated, with competition driven by the presence of major life sciences and bioprocessing companies offering advanced cell culture and biomanufacturing solutions. Leading companies including Thermo Fisher Scientific, Merck KGaA, Cytiva, Sartorius AG, and FUJIFILM Irvine Scientific maintain strong market positions with a combined market share of approximately 76.5%. These players sustain their leadership through extensive serum-free and chemically defined media portfolios, strong global manufacturing capabilities, and broad distribution networks.

Market participants primarily compete based on media performance, customization capabilities, regulatory compliance, scalability, pricing, and technical support services. Companies are increasingly focusing on developing application-specific and high-performance serum-free media formulations optimized for biologics manufacturing, vaccine production, stem cell research, and cell & gene therapy applications. In addition, the rapid expansion of biologics pipelines and advanced therapy medicinal products (ATMPs) is encouraging manufacturers to strengthen collaborations with biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and research institutions.

Serum-free Media Market Companies

A few of the prominent players operating in the serum-free media industry include:

• ACROBiosystems
• Biowest
• Corning
• Cytiva
• Cellplus Bio
• Elabscience
• Eminence Scientific
• FUJIFILM Irvine Scientific
• JSBio
• Lonza
• Merck KGaA
• Miltenyi Biotec
• MP Biomedicals
• PromoCell
• PAN-Biotech
• Sartorius
• Sino Biological
• Thermo Fisher Scientific

• Thermo Fisher Scientific

Thermo Fisher Scientific offers a comprehensive portfolio spanning classical media, specialty media, and advanced formulations such as serum-free and chemically defined media. The company leverages its strong global manufacturing footprint and well-established brands (e.g., Gibco) to serve biopharmaceutical production, research, and clinical applications.

• Merck

Merck KGaA is a key player in the serum-free media market, operating through its Life Science segment. The company offers a broad portfolio of cell culture media, including classical, specialty, and chemically defined formulations, catering to both research and biopharmaceutical manufacturing applications. With its global manufacturing network, strong R&D capabilities, and strategic investments in bioprocessing, the company continues to strengthen its position in the market.

Serum-free Media Industry News:

• In April 2025, Asimov and Cytiva partnered to offer an integrated biologics production solution, combining CHO Edge cell line development, HyClone media, and Fast Trak services. This collaboration supports efficient expression of complex protein biologics, enhancing therapeutic development and accelerating innovation in life sciences. This alliance aims to strengthen biologics manufacturing and contribute to the expanding cell culture media demand by driving demand for advanced, customizable media solutions tailored to next-generation therapies.
• In January 2024, JSBio officially opened its second cell culture media manufacturing facility in Nantong, China, complementing JSBio’s existing operations in Lanzhou and Shanghai, marking a major milestone in its expansion strategy and commitment to global biomanufacturing excellence.
• In February 2024, ProBio entered a strategic partnership with Cell Resources Corporation, a subsidiary of Alfresa Holdings Corporation in Japan, to advance cell therapy development through a synergistic CDMO framework. The initiative was positioned to reduce R&D costs and accelerate commercialization of regenerative medicine innovations across Japan and global markets.
• In September 2023, Eminence Biotechnology launched its advanced facility for commercial cell culture media production, addressing rising demand across vaccines, gene therapies, antibodies, and recombinant proteins. The new site supports scalable, high-quality media manufacturing tailored to evolving therapeutic needs. This expansion strengthens Eminence’s role in the rapidly growing cell culture media market, meeting increasing global demand for specialized, GMP-compliant media essential to next-generation biologics and cell-based therapies.

The serum-free media market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 - 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• CHO media
• HEK 293 media
• BHK media
• VERO cell media
• Insect cell media
• Immune cell media
• Other serum-free media

Market, By Form

• Liquid media
• Semi-solid and solid media

Market, By Application

• Biopharmaceutical production
• Vaccine production
• Drug discovery & development
• Stem cell research & therapy
• Tissue engineering & regenerative medicine
• Other applications

Market, By End Use

• Pharmaceutical & biotechnology companies
• Clinical research organizations (CROs)
• Academic & research institutions
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE